These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31668946)

  • 1. Paradigms for Precision Medicine in Epichaperome Cancer Therapy.
    Pillarsetty N; Jhaveri K; Taldone T; Caldas-Lopes E; Punzalan B; Joshi S; Bolaender A; Uddin MM; Rodina A; Yan P; Ku A; Ku T; Shah SK; Lyashchenko S; Burnazi E; Wang T; Lecomte N; Janjigian Y; Younes A; Batlevi CW; Guzman ML; Roboz GJ; Koziorowski J; Zanzonico P; Alpaugh ML; Corben A; Modi S; Norton L; Larson SM; Lewis JS; Chiosis G; Gerecitano JF; Dunphy MPS
    Cancer Cell; 2019 Nov; 36(5):559-573.e7. PubMed ID: 31668946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chaperome heterogeneity and its implications for cancer study and treatment.
    Wang T; Rodina A; Dunphy MP; Corben A; Modi S; Guzman ML; Gewirth DT; Chiosis G
    J Biol Chem; 2019 Feb; 294(6):2162-2179. PubMed ID: 30409908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring Tumor Epichaperome Expression Using [
    Jhaveri KL; Dos Anjos CH; Taldone T; Wang R; Comen E; Fornier M; Bromberg JF; Ma W; Patil S; Rodina A; Pillarsetty N; Duggan S; Khoshi S; Kadija N; Chiosis G; Dunphy MP; Modi S
    JCO Precis Oncol; 2020; 4():. PubMed ID: 33283132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of
    Sharma S; Kalidindi T; Joshi S; Digwal CS; Panchal P; Burnazi E; Lee SG; Pillarsetty N; Chiosis G
    STAR Protoc; 2022 Jun; 3(2):101318. PubMed ID: 35496791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
    Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
    Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.
    Speranza G; Anderson L; Chen AP; Do K; Eugeni M; Weil M; Rubinstein L; Majerova E; Collins J; Horneffer Y; Juwara L; Zlott J; Bishop R; Conley BA; Streicher H; Tomaszewski J; Doroshow JH; Kummar S
    Invest New Drugs; 2018 Apr; 36(2):230-239. PubMed ID: 28808818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The epichaperome is an integrated chaperome network that facilitates tumour survival.
    Rodina A; Wang T; Yan P; Gomes ED; Dunphy MP; Pillarsetty N; Koren J; Gerecitano JF; Taldone T; Zong H; Caldas-Lopes E; Alpaugh M; Corben A; Riolo M; Beattie B; Pressl C; Peter RI; Xu C; Trondl R; Patel HJ; Shimizu F; Bolaender A; Yang C; Panchal P; Farooq MF; Kishinevsky S; Modi S; Lin O; Chu F; Patil S; Erdjument-Bromage H; Zanzonico P; Hudis C; Studer L; Roboz GJ; Cesarman E; Cerchietti L; Levine R; Melnick A; Larson SM; Lewis JS; Guzman ML; Chiosis G
    Nature; 2016 Oct; 538(7625):397-401. PubMed ID: 27706135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.
    Dunphy MPS; Pressl C; Pillarsetty N; Grkovski M; Modi S; Jhaveri K; Norton L; Beattie BJ; Zanzonico PB; Zatorska D; Taldone T; Ochiana SO; Uddin MM; Burnazi EM; Lyashchenko SK; Hudis CA; Bromberg J; Schöder HM; Fox JJ; Zhang H; Chiosis G; Lewis JS; Larson SM
    Clin Cancer Res; 2020 Oct; 26(19):5178-5187. PubMed ID: 32366671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Companion Diagnostics and Molecular Imaging.
    Puranik AD; Kulkarni HR; Baum RP
    Cancer J; 2015; 21(3):213-7. PubMed ID: 26049701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chaperome Networks - Redundancy and Implications for Cancer Treatment.
    Yan P; Wang T; Guzman ML; Peter RI; Chiosis G
    Adv Exp Med Biol; 2020; 1243():87-99. PubMed ID: 32297213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia.
    Sugita M; Wilkes DC; Bareja R; Eng KW; Nataraj S; Jimenez-Flores RA; Yan L; De Leon JP; Croyle JA; Kaner J; Merugu S; Sharma S; MacDonald TY; Noorzad Z; Panchal P; Pancirer D; Cheng S; Xiang JZ; Olson L; Van Besien K; Rickman DS; Mathew S; Tam W; Rubin MA; Beltran H; Sboner A; Hassane DC; Chiosis G; Elemento O; Roboz GJ; Mosquera JM; Guzman ML
    NPJ Precis Oncol; 2021 May; 5(1):44. PubMed ID: 34040147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane protein-regulated networks across human cancers.
    Lin CY; Lee CH; Chuang YH; Lee JY; Chiu YY; Wu Lee YH; Jong YJ; Hwang JK; Huang SH; Chen LC; Wu CH; Tu SH; Ho YS; Yang JM
    Nat Commun; 2019 Jul; 10(1):3131. PubMed ID: 31311925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Companion Diagnostics to Identify Biomarkers of Response to Anticancer Drugs Targeting the Proteome.
    Joshua AM; Tannock IF
    Cancer Cell; 2019 Nov; 36(5):464-465. PubMed ID: 31715128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theranostics and metabolotheranostics for precision medicine in oncology.
    Bhujwalla ZM; Kakkad S; Chen Z; Jin J; Hapuarachchige S; Artemov D; Penet MF
    J Magn Reson; 2018 Jun; 291():141-151. PubMed ID: 29705040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferation.
    Roychowdhury T; McNutt SW; Pasala C; Nguyen HT; Thornton DT; Sharma S; Botticelli L; Digwal CS; Joshi S; Yang N; Panchal P; Chakrabarty S; Bay S; Markov V; Kwong C; Lisanti J; Chung SY; Ginsberg SD; Yan P; De Stanchina E; Corben A; Modi S; Alpaugh ML; Colombo G; Erdjument-Bromage H; Neubert TA; Chalkley RJ; Baker PR; Burlingame AL; Rodina A; Chiosis G; Chu F
    Nat Commun; 2024 Oct; 15(1):8912. PubMed ID: 39414766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimuli-Responsive Nanotheranostics for Real-Time Monitoring Drug Release by Photoacoustic Imaging.
    Yang Z; Song J; Tang W; Fan W; Dai Y; Shen Z; Lin L; Cheng S; Liu Y; Niu G; Rong P; Wang W; Chen X
    Theranostics; 2019; 9(2):526-536. PubMed ID: 30809290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.
    Srivas R; Shen JP; Yang CC; Sun SM; Li J; Gross AM; Jensen J; Licon K; Bojorquez-Gomez A; Klepper K; Huang J; Pekin D; Xu JL; Yeerna H; Sivaganesh V; Kollenstart L; van Attikum H; Aza-Blanc P; Sobol RW; Ideker T
    Mol Cell; 2016 Aug; 63(3):514-25. PubMed ID: 27453043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theranostic barcoded nanoparticles for personalized cancer medicine.
    Yaari Z; da Silva D; Zinger A; Goldman E; Kajal A; Tshuva R; Barak E; Dahan N; Hershkovitz D; Goldfeder M; Roitman JS; Schroeder A
    Nat Commun; 2016 Nov; 7():13325. PubMed ID: 27830705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine?
    Blau R; Krivitsky A; Epshtein Y; Satchi-Fainaro R
    Drug Resist Updat; 2016 Jul; 27():39-58. PubMed ID: 27449597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting stressor-induced dysfunctions in protein-protein interaction networks via epichaperomes.
    Ginsberg SD; Sharma S; Norton L; Chiosis G
    Trends Pharmacol Sci; 2023 Jan; 44(1):20-33. PubMed ID: 36414432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.